Cyclin-dependent kinase activity is required for efficient expression and posttranslational modification of human cytomegalovirus proteins and for production of extracellular particles.
We have previously shown that the addition of the cyclin-dependent kinase (cdk) inhibitor Roscovitine at the beginning of infection of cells with human cytomegalovirus (HCMV) significantly disrupts immediate-early gene expression and the progression of the infection. In the present study, we have examined the effects of cdk inhibition on late viral events by delaying addition of Roscovitine until 24 h postinfection. Although viral DNA replication was inhibited two- to threefold by treatment of infected cells with Roscovitine, the drop did not correspond to the 1- to 2-log-unit decrease in virus titer. Quantification of viral DNA in the supernatant from cells revealed that there was a significant reduction in the production or release of extracellular particles. We observed a lag in the expression of several viral proteins but there was a significant decrease in the steady-state levels of IE2-86. Likewise, the steady-state level of the essential tegument protein UL32 (pp150) was reduced. The levels of pp150 and IE2-86 mRNA were not greatly affected by treatment with Roscovitine and thus did not correlate with the reduced levels of protein. In contrast, the expression of the tegument protein ppUL69 was higher in drug-treated samples, and the protein accumulated in a hyperphosphorylated form. ppUL69 localized to intranuclear aggregates that did not overlap with viral replication centers in cells treated with Roscovitine. Taken together, these data indicate that cdk activity is required at multiple steps during HCMV infection, including the expression, modification, and localization of virus-encoded proteins.
Sanchez
Veronica
V
Department of Cellular and Molecular Medicine, University of California, San Diego, La Jolla, CA 92093-0712, USA.
Spector
Deborah H
DH
D002460:Cell Line; D018844:Cyclin-Dependent Kinases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D003587:Cytomegalovirus / Q000737:chemistry* / Q000502:physiology; D004279:DNA, Viral / Q000032:analysis; D005347:Fibroblasts / Q000166:cytology / Q000821:virology; D015967:Gene Expression Regulation, Viral / Q000187:drug effects; D006801:Humans; D011499:Protein Processing, Post-Translational; D011687:Purines / Q000494:pharmacology; D000077546:Roscovitine; D014764:Viral Proteins / Q000096:biosynthesis*; D014771:Virion; D014779:Virus Replication / Q000187:drug effects
D004279:DNA, Viral; D011687:Purines; D014764:Viral Proteins; D000077546:Roscovitine; D018844:Cyclin-Dependent Kinases